TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04885452

Intervention type: OTHER
Intervention: biobank
Description: * Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5

Intervention type: OTHER
Intervention: biobank
Description: * Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5

Intervention type: OTHER
Intervention: biobank
Description: * Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5

Intervention type: OTHER
Intervention: biobank
Description: * Blood samples (biobank) at Day 0, Day 7, Month 1 and possibly Month 3 (only for the first 100 participants) (serum, plasma and whole blood)~* For participants in the immunological ancillary study: additional blood sampling at Day 0, Day 7 and Month 1 (PBMC)~* Nasopharyngeal swabs: Day 0, Day 7 (Day 14 and Day 21 if RT-PCR positive respectively at Day 7 and Day 14)~* Specific nasopharyngeal swabs in hospitalized patients: Day 3, Day 5
Study: NCT05125263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping group
Description: Kinesio-taping with conventional therapy 24, 48 and 72 hours standardized therapeutic KT application along with conventional therapy (hot pack, strengthening and stretching exercises). The patient laid supine.To maintain proprioceptive stimulation in the quadriceps (from origin towards insertion) and to alleviate the tension of hamstring muscle, a 'Y'-shaped kinesiotaping will be applied. Afterward, 2 pieces of 'I'-shaped tapes were stretched by 75% through the mechanical correction technique and will be applied around the patellar circumference in the way that it would allow the patella to move naturally in the femoral cavity while the knee was in 45 flexion~CONVENTIONAL THERAPY:~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan taping group
Description: Mulligan taping will be applied while patient in standing position and the hip, knee will be internally rotated and flexed to 20 degree. Rigid tape will be applied from neck of fibula which will be passing anteriorly over the tibia to secure internal rotation of tibia at the knee, and passing below the medial joint line and behind the knee, 2 superimposed layers of 38-mm rigid tape will be applied in a spiral fashion. Tape will be applied for 24, 48 and 72 hours. And it must come off immediately if any pain and skin irritation is experienced. Along with conventional therapy.~Stretching of hamstrings 10 reps 10 sec hold. Straight leg raise 3 sets\* 10 reps, 1 min interval. Strengthening of Quadriceps (quads isometric) and VMO with 10 reps and 3 sets, 1 min interval) Squatting (10 reps\* 3 sets, 1 min interval)
Study: NCT06243536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide will be administered through 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Patients not assigned to receive semaglutide will receive standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Patients not assigned to receive semaglutide will receive standard of care.
Study: NCT06203743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block group
Description: PI, PVI measurements and hemodynamic data will be compared between groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ilioinguinal-iliohypogastric nerve block group
Description: PI, PVI measurements and hemodynamic data will be compared between groups
Study: NCT05722392

Intervention type: PROCEDURE
Intervention: Two-step Radical Prostatectomy
Description: The first step is enucleation of the hyperplastic adenoma, and the second step is anterograde RP to residual gland
Study: NCT04341246

Intervention type: DEVICE
Intervention: LiverMultiscan
Description: The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation

Intervention type: DEVICE
Intervention: LiverMultiscan
Description: The Livermultiscan is a quick, 15 minute contrast free MRI scan that provided metrics to quantify liver health namely fat, iron and fibro-inflammation
Study: NCT04268667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Application of upper cervical spine thrust joint manipulation or application of a full combination of cervical, cervico-thoracic and thoracic spine thrust joint manipulation.
Study: NCT05006963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy and therapy by exercise
Description: In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and therapy by exercise
Description: In general, patients will receive extra-oral massage and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will bemouth opening exercise was also performed with the tongue on the palate, proprioceptive lateralization and protrusion exercises with hyperboloid and exercises with combinations of movements of laterality and opening, or protrusion and opening.
Study: NCT06218797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a routine sedation protocol
Description: In this study group, a routine sedation protocol in our clinic will be applied in the endoscopic unit. Premedication will not be given to the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized with dexmedetomidine
Description: Patients will be received nebulisation with dexmedetomidine 2mcg/kg 5 cc 20 minute prior to endoscopy. After that routine sedation protocol in our clinic will be applied.
Study: NCT06201026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercise
Description: Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional exercise
Description: Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized exercise
Description: Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized exercise
Description: Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.
Study: NCT05255900

Intervention type: DRUG
Intervention: Metyrapone Capsules
Description: Exposure to 24 weeks of treatment with metyrapone
Study: NCT05994482

Intervention type: OTHER
Intervention: adenoma vs no adenoma
Description: For Aim 1, the investigators will examine colorectal cancer risk among older adults with prior removal of a precancerous polyp (adenoma) vs a prior normal colonoscopy

Intervention type: OTHER
Intervention: colonoscopy vs no colonoscopy
Description: For Aim 2, the investigators will examine colorectal cancer risk among older adults with prior history of polypectomy, exposed vs unexposed to subsequent surveillance colonoscopy

Intervention type: OTHER
Intervention: survey and expert panel
Description: The investigators will conduct 44 semi-structured one-on-one qualitative interviews with VA patients (older adults) and providers (primary care, GI, geriatrics) to understand perspectives on CRC risk, and potential benefits and harms of surveillance (Aim 3a). The investigators will then convene an expert panel with key stakeholders including Veterans, primary providers, geriatricians, gastroenterologists, VA leaders, and policy makers to present Aim 1, 2, and 3a findings (Aim 3b). The primary outcome will be specific recommendations regarding use of surveillance colonoscopy in older adults, ranked by priority and feasibility, that can guide VA policy around future implementation (or de-implementation) of surveillance among older adults.
Study: NCT05163522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT04589208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: We will assign ketamine doses in successive 10 subject cohorts. The ketamine dose for the 1st cohort will start at 0.08 mg/kg. For subsequent cohorts, the bolus will be successively reduced or increased by 0.02 mg/kg (n=10/dose) to determine the lowest dose of ketamine that still produces a robust phBOLD response
Study: NCT05158998

Intervention type: DRUG
Group type: OTHER
Intervention: propofol infusion
Description: For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)).Propofol infusion will be stopped at the end of surgery.
Study: NCT05163522

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered
Study: NCT05370196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Product
Description: Synthetic Male Condom

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Product
Description: Latex Male Condom
Study: NCT05019144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face burn care
Description: If the participants are assigned to FTF care, they will receive standard burn care including a return follow-up in the burn clinic on a routine basis as prescribed by the clinical burn team (at least once per week) until the burn has healed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine enhanced burn care
Description: Participants assigned to TOBI will be given instructions how to download and use TOBI on a smartphone, including how to interface with burn clinicians using text-messaging, videoconferencing, and sending photos of the child's burn(s). The participants will have scheduled video visits with the care provider at least weekly until the burn has healed. The participants will be able to use other features of the app, such as text-messaging and sending photos of the burn(s), as needed. The participants will be able to use standard FTF burn care as well. They will be given instructions how to contact the burn team through the hospital paging operator if TOBI is unavailable or there is an emergency.
Study: NCT04893369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Low Back Pain and Disability Drivers Management model
Description: PTs assigned to the intervention arm will undergo a one-day training specific to the PDDM model. The objectives of the workshop are 1) to acquire knowledge on the functioning of the PDDM model by identifying the different domains of the model, and the specific elements that are deemed problematic for a given patient to appropriately establish the clinical profile and 2) to adopt a structured approach to manage and select appropriate interventions to address problematic areas. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers, 2) nervous system dysfunction (NSD) drivers, 3) comorbidity drivers, 4) cognitive-emotional drivers and 5) contextual drivers. This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low back pain clinical practice guidelines
Description: For the PTs allocated to the control arm, they will participate in a three-hour training on the most recent CPGs on the management of LBP. The content of the training is based on the results of a thorough review of the literature summarizing the different recommendations from CPGs with a focus on the rehabilitation management of LBP. The objectives of the workshop are 1) to acquire knowledge about the recommendations from the most recent and high-quality CPGs for the management of LBP and 2) to foster their integration into clinical practice. An interactive workshop will be conducted to present the results of the review of the literature with the help of case-studies to facilitate implementation and promote active participation.
Study: NCT05127733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioural Therapy
Description: Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioural Therapy
Description: Interactive program utilizing cognitive behavioural therapy principles that guides users through its components and provides feedback, which facilitates behavior change (i.e., reduction in alcohol or substance use).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Peer Support
Description: Weekly meetings with a trained peer support worker who guides participants through the BFO platform, reviews the platform's content with them, and supports them in the creation of an action strategy based on the platform's suggestions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Peer Support
Description: Meetings with a group of peers led by a trained peer support worker/volunteer which will offer the participants an opportunity to discuss their experiences in a supportive and open environment.
Study: NCT05158998

Intervention type: DRUG
Group type: OTHER
Intervention: sevoflurane inhalation
Description: For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
Study: NCT05441254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab; Nab-paclitaxel; S-1
Description: Camrelizumab: 200 mg, intravenous infusion, d1, q3w;~Nab-paclitaxel: 130 mg/m2 intraperitoneal and 130 mg/m2 intravenously, d1, q3w;~S-1: calculated based on body surface area Dosage, twice a day, orally, d1-d14, q3w;~The dosage can be adjusted according to the protocol according to the adverse reactions of subjects. Subjects will continue to take medication until completion of the prescribed course of treatment, disease progression, toxicity intolerance, withdrawal of Informed Consent Form, or termination in the investigator's judgment.
Study: NCT05698550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erzhi Tiangui Granule
Description: The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erzhi Tiangui Placebo
Description: The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
Study: NCT04971434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulation for acupoints
Description: In fatty liver patients (30 patients), a daily application of 4-minute laser (for one month, except Fridays) on acupoint number 25,40,36 of stomach meridian, acupoint number 3 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9,12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cupping with scarification
Description: In fatty liver patients (30 patients),every-two-week applied cupping (with scarification) session within one month on back of upper thorax
Study: NCT04772001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochloride anlotinib
Description: Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets. It will be taken at a starting dose of 12 mg for 14 days. Then participants will rest for 7 days and start a new cycles. At most of 3 cycles will be administrated. If intolerable toxicity happen, dosage of 10mg or 8mg will be taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis Platinum/carboplatin
Description: Concurrent chemotherapy will be administrated weekly during radiation for a total of 5-6 doses. Cisplatin of 40mg/m2 will be the most preferred regime. For patients with intolerable toxicity of cisplatin, carboplatin of AUC 2 will be the alternative drug.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy and brachytherapy
Description: Radiation will be given by external beam of 45Gy total dose and 3D-brachytherapy of 30Gy/5F or 28Gy/4F. Duration of radiotherapy will be no more than 8 weeks.
Study: NCT04862585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: Given IV and/or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV and/or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Given IV and/or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Given IV and/or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Weekly or every 14 day dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly or every 14 day dosing
Study: NCT01079338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine
Study: NCT05202548

Intervention type: OTHER
Intervention: Immuno-histochemical staining
Description: blocked paraffin that suit with inclusion and exclusion criteria proceed with immuno-histochemical staining to define immune dysregulation in lymphadenitis TB
Study: NCT05166980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mutiply-fortified salt
Description: Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mutiply-fortified salt
Description: Salt fortified with iron, zinc, vitamin B12, folic acid, and iodine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iodized salt
Description: Salt fortified with iodine
Study: NCT06485362

Intervention type: DIAGNOSTIC_TEST
Intervention: Termography
Description: Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).

Intervention type: DIAGNOSTIC_TEST
Intervention: Termography
Description: Thermographic images of both feet will be taken in multiple views (dorsal, plantar, lateral).
Study: NCT04862585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06444685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and cognitive training interventino
Description: Exercise and cognitive training based on Table tennis and Tabletop games.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and cognitive training interventino
Description: Exercise and cognitive training based on Table tennis and Tabletop games.